大黄虫丸联合化疗治疗中晚期原发性肝癌的临床观察  

Pill of DaHuang ZheChongWan with Chemotherapy in the Treatment of Primary Carcinoma of Liver at Middle-advanced Stage

作　　者：吴洁[1] 申弘道[1] 

机构地区：[1]广西中医学院,广西南宁530001

出　　处：《西部中医药》2011年第10期54-55,共2页Western Journal of Traditional Chinese Medicine

摘　　要：目的:观察大黄虫丸联合化疗治疗中晚期原发性肝癌的临床疗效。方法:将52例中晚期原发性肝癌患者随机分为治疗组和对照组,每组各26例,治疗组用大黄虫丸联合化疗治疗,对照组进行单纯化疗,2个周期后比较2组近期疗效、生存率及毒副反应。结果:治疗组患者在近期疗效、0.5～2年的生存率方面明显优于对照组,同时治疗组的毒副反应低于对照组(P<0.05)。结论:大黄虫丸联合化疗治疗中晚期原发性肝癌,可提高疗效及患者生存率,同时可减轻化疗的毒副反应。Objective：To observe clinical effects of DaHuang ZheChongWan and chemotherapy in the treatment of primary carcinoma of liver at middle-advanced stage.Method：52 patients with primary carcinoma of liver at middle-advanced stage are randomly classified into treatment group and control group,each group 26 patients.The patients in treatment group are treated with DaHuang ZheChongWan and chemotherapy,while the ones in control group are only given chemotherapy.Both groups are medicated for two cycles.To compare recent effects,survival rate,toxic reactions of two groups.Result：recent effects,survival rate from half of a year to two years of the patients in treatment group are better than control group.At the same time,toxic reactions of treatment group are lower than of control group（P0.05）.Conclusion：DaHuang ZheChongWan with chemotherapy in the treatment of primary carcinoma of liver at middle-advanced Stage can improve the efficacy and survival rate of the patient as well as alleviate the toxicity and side effects of chemotherapy.

关 键 词：原发性肝癌 大黄虫丸 化疗 

分 类 号：R735.7[医药卫生—肿瘤]